People: Shire PLC (SHP.L)

SHP.L on London Stock Exchange

4,864.00GBp
1 Sep 2014
Price Change (% chg)

-59.00p (-1.20%)
Prev Close
4,923.00p
Open
4,904.00p
Day's High
4,915.00p
Day's Low
4,844.00p
Volume
712,881
Avg. Vol
3,365,122
52-wk High
5,050.00p
52-wk Low
2,373.00p

Search Stocks

Summary

Name Age Since Current Position

Susan Kilsby

55 2014 Non-Executive Chairman of the Board

Flemming Ornskov

56 2013 Chief Executive Officer, Director

David Kappler

66 2008 Senior Independent Non-Executive Deputy Chairman of the Board

James Bowling

45 2014 Interim Chief Financial Officer

Tatjana May

47 General Counsel, Company Secretary

Dominic Blakemore

44 2014 Non-Executive Director

William Burns

66 2010 Non-Executive Independent Director

Steven Gillis

50 2012 Non-Executive Independent Director

David Ginsburg

61 2010 Non-Executive Independent Director

Anne Minto

60 2010 Non-Executive Independent Director

David Stout

59 2009 Non-Executive Independent Director

Biographies

Name Description

Susan Kilsby

Ms. Susan Saltzbart Kilsby has been appointed as Non-Executive Chairman of the Board of Shire Plc., effective April 29, 2014. Susan is also a Non-Executive Director of BBA Aviation plc, Coca-Cola HBC AG and Green Mountain Coffee Roasters Inc. Susan has served as a part-time Senior Advisor to Credit Suisse Group AG since 2009 and this role will conclude when she becomes Chairman. Earlier in her career, during her more than 30 years at Credit Suisse, she served as Chairman of Mergers & Acquisitions, EMEA and Vice Chairman of the European Investment Banking Committee, and also led the European Consumer, Retail & Services Investment Banking Group. Her career in global investment banking also includes senior positions with Barclays de Zoete Wedd, Bankers Trust and The First Boston Corporation. She serves as the International Regional Chair of the Committee of 200 and was a founding Member of the Competitor Diversity Forum. She is a Visiting Fellow of the Cass Business School and is Chairman of the M&A Research Centre at Cass. Susan also serves on the Advisory Board of the Yale School of Management and is a Member of the Business Leadership Council of Wellesley College. An American national with UK citizenship, Susan gained her first degree in Economics at Wellesley College and her MBA at Yale School of Management. She has homes in the US and in Europe.

Flemming Ornskov

Dr. Flemming Ornskov, M.D., MBA, MPH, has been appointed as Chief Executive Officer, Director of Shire Plc., effective April 30, 2013. Dr. Ornskov was appointed Chief Executive Officer Designate and a member of the Board on January 2, 2013. He is Non-Executive Chairman of Evotec AG and is a former Non-Executive Director of PCI Biotech Holding ASA. Dr. Ornskov held the position of Chief Marketing Officer and Global Head, Strategic Marketing for General and Specialty Medicine at Bayer from 2010 to 2012. Prior to joining Bayer, Dr. Ornskov served as Global President, Pharmaceuticals and OTC at Bausch & Lomb, Inc., from 2008 to 2010. He also served as Chairman and later as President and Chief Executive Officer of Life-Cycle Pharma A/S from 2006 to 2008, and President and Chief Executive Officer of Ikaria, Inc., from 2005 to 2006. Earlier in his pharmaceutical career he had roles of increasing responsibility at Merck & Co. Inc. and Novartis AG, following a distinguished period in hospital and academic medicine. Dr. Ornskov received his MD from the University of Copenhagen, MBA from INSEAD, and Master of Public Health from Harvard University.

David Kappler

Mr. David J. Kappler is Senior Independent Non-Executive Deputy Chairman of the Board of Shire Plc., since June 2008. Mr. Kappler has been a member of the Board since April 5, 2004. He was appointed Senior Independent Non-Executive Director in July 2007 and Deputy Chairman in June 2008. He is also Chairman of the Nomination Committee and of the Audit, Compliance & Risk Committee. He is a Non-Executive Director of InterContinental Hotels Group plc. He was Chairman of Premier Foods plc until September 2010 and held directorships at Camelot Group plc and HMV Group plc. Mr. Kappler retired from Cadbury Schweppes plc in April 2004 after serving as Chief Financial Officer since 1995. He worked for the Cadbury Schweppes Group between 1965 and 1984 and rejoined the company in 1989 following its acquisition of the Trebor Group, where he was Financial Director. Mr. Kappler is a Fellow of the Chartered Institute of Management Accountants.

James Bowling

Mr. James Bowling has been appointed as Interim Chief Financial Officer of the Company effective March 1, 2014. He joined Shire in 2005 and during this time has been a key leader in Shire's finance team for the past nine years. He has led Shire's financial reporting, financial planning & analysis, and treasury & insurance teams. As part of his role, James has had regular interaction with the Company's Board of Directors, in particular supporting the Audit, Compliance & Risk Committee and the Remuneration Committee.

Tatjana May

Ms. Tatjana May is General Counsel, Company Secretary of Shire Plc. She has been with Shire since May 2001. Ms. May was previously Assistant General Counsel at the corporate headquarters of AstraZeneca plc. Prior to that she worked at the law firm Slaughter and May.

Dominic Blakemore

Mr. Dominic Blakemore has been appointed as Non-Executive Director of Shire Plc., with effective 1 January 2014. Dominic is Group Finance Director of Compass Group PLC. Prior to this he was Chief Financial Officer at Iglo Foods Group and Finance & Strategy Director of Cadbury plc. He spent his earlier career years at PwC (PricewaterhouseCoopers), where his work included advising pharmaceutical sector clients.

William Burns

Mr. William Burns is Non-Executive Independent Director of Shire Plc., since March 15, 2010. He was appointed to the Board on March 15, 2010 and is a member of the Remuneration Committee, the Nomination Committee and of the Science & Technology Committee. Mr. Burns brings to the Board experience in international sales, marketing, integration and operational experience in the pharmaceutical sector. He is a Director of Biotie Therapies Corp., Roche Holdings Ltd, Chugai Pharmaceutical Co., Ltd and Genentech, Inc. and is a former Director of Crucell N.V. Mr. Burns worked for many years for Roche, holding the position of CEO of their pharmaceuticals division from 2005 to 2009 and was a member of the Roche Group Corporate Executive Committee. Mr. Burns holds a BA (Hons).

Steven Gillis

Dr. Steven Gillis, Ph.D. has been appointed as Non-Executive Independent Director of Shire plc., effective October 1, 2012. Dr. Gillis is a member of the Science & Technology Committee and the Remuneration Committee. Dr. Gillis is currently a Managing Director at ARCH Venture Partners, a provider of venture capital for technology firms, where he is focused on the evaluation of new life science technologies and the development and growth of ARCH’s biotechnology portfolio companies. Prior to this, Dr. Gillis was a founder and director of Corixa Corporation, acquired by GlaxoSmithKline in 2005. Prior to starting Corixa, he was a founder and director of Immunex Corporation. An immunologist by training, Dr. Gillis has authored more than 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20) and the novel vaccine adjuvant, MPL. Dr. Gillis received his BA from Williams College and his Ph.D. from Dartmouth College.

David Ginsburg

Dr. David Ginsburg, M.D., is Non-Executive Independent Director of Shire Plc., since June 16, 2010. He is a member of the Science & Technology Committee. He is currently James V. Neel Distinguished University Professor of Internal Medicine Human Genetics, and Pediatrics at the University of Michigan and a Howard Hughes Medical Institute Investigator. Dr. Ginsburg obtained his BA at Yale University, MD at Duke University and completed his medical and research training at Harvard Medical School, before joining the faculty at the University of Michigan. Dr. Ginsburg is the recipient of numerous honors and awards, including election to membership in the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences.

Anne Minto

Ms. Anne Minto, OBE, is Non-Executive Independent Director of Shire Plc., since June 16, 2010. Ms. Minto is Chairman of the Remuneration Committee and a member of the Nomination Committee. She is a Non-Executive Director of Tate & Lyle PLC and is a former Director of Northumbrian Water plc and SITA UK. Ms. Minto held the position of Group Director, Human Resources at Centrica plc from October 2002 to 30 June 2011 and was a member of the Centrica Executive Committee. Her business career includes senior management roles at Shell UK, the position of Deputy Director-General of the Engineering Employers’ Federation and the position of Group Director Human Resources at Smiths Group plc. Following her law degree at Aberdeen University and a post graduate diploma in Human Resources she qualified as a lawyer. Ms. Minto is a Fellow of the Chartered Institute of Personnel & Development, the Royal Society of Arts and the London City and Guilds and a Member of Law Society of Scotland. She is a trustee of the University of Aberdeen Development Trust and is Patron of the University of Aberdeen Alumni Fund.

David Stout

Mr. David M. Stout is Non-Executive Independent Director of Shire Plc., since October 31, 2009. Mr. Stout is a member of the Audit, Compliance & Risk Committee and of the Remuneration Committee. He is a Director of Jabil Circuit, Inc. and Airgas Inc. and is a former Director of Allos Therapeutics, Inc. Mr. Stout was President, Pharmaceutical Operations at GlaxoSmithKline, where he was responsible for the company’s global pharmaceutical operations, from January 2003 to February 2008. Prior to that, he was President of GlaxoSmithKline’s US Pharmaceuticals Business and before that SmithKline Beecham’s North American Pharmaceuticals Business. Before joining SmithKline Beecham, Mr. Stout worked for many years at Schering-Plough. Mr. Stout holds a BA in biology.

Basic Compensation

Name Fiscal Year Total

Susan Kilsby

109,486

Flemming Ornskov

3,402,000

David Kappler

133,586

James Bowling

--

Tatjana May

--

Dominic Blakemore

--

William Burns

--

Steven Gillis

--

David Ginsburg

--

Anne Minto

--

David Stout

--
As Of 30 Dec 2013
Search Stocks